33378 Rheda-Wiedenbrück, de
+44 (20) 32177065
NSF International's Pharma Biotech Experts to Share Industry Insights and Predictions at CPhI 2018York, UK, )
With Brexit and a changing regulatory landscape key focuses in the sector, NSF International’s Executive Director Lynne Byers will be at the show to give expert guidance and present on “The Potential Impacts of Brexit,” which is also the subject of a media breakfast hosted by the organization on October 10th.
Lynne comments: “The potential impact of Brexit spells significant levels of uncertainty over the coming years as, as far as the EU is concerned, the UK will effectively become a third country from 29 March 2019. The many scenarios that are possible each have challenges attached for the pharma biotech industry, particularly as the UK is looking at leaving the EEA, and in order to protect supply chains and avoid issues with the supply of medicines, a sensible, pragmatic approach to decision-making from both the UK and EU camps is required. Regardless of the outcome, NSF is well placed to advise on how best to negotiate the situations that will result, and visitors to our stand can learn more on our approach first hand.”
With more than 35 years of extensive pharmaceutical manufacturing management and QA auditing of a wide range of pharmaceutical manufacturers, Lynne has a wealth of knowledge to share on the current EU and FDA GMP regulations and requirements. She also has extensive experience in managing QA teams in country affiliates and is a former QP assessor on behalf of the Royal Society of Chemistry. Her credentials won her a prominent spot on the CPhI panel of experts, as the host of an afternoon session on October 10th. Lynne will be sharing her knowledge and expertise on the complexities of the pharma supply chain and how legislation can be utilised to effectively identify and manage risks in this area.
Lynne is also one of 10 C-Level representatives participating in a closed-door C-Suite Roundtable later today, in which senior pharma executives will discuss key topics, including policy, growth, regulation, regional and global challenges. NSF International is honoured to have been chosen as one of the participants of this first time event, aimed at sharing ideas and strategies on what the industry needs to move forward.
Pharma biotech is a complex industry and even the largest organisations will sometimes need guidance in terms of navigating the regulatory landscape and maintaining best practice. NSF International specialises in protecting and improving human health through consulting, training, auditing, testing certification and legislative guidance, and visitors to the stand will be able to experience the organization’s blended approach to learning first hand. The NSF International specialists are on hand to demonstrate the organization’s wide range of content, incorporating public courses - which can also be tailored and customised to be run on client sites - and interactive eLearning sessions - which can be attended on-the-go, at home or at a time that is most convenient.
To learn more about NSF’s work in the pharma biotech arena, visit stand 3G63 in Hall 3.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.